Admera Health, Orlando, Fla, has launched the CardioGxOne genetic testing panel for inherited cardiovascular diseases.
Developed as a joint venture between Admera Health and Health in Code, La Coruña, Spain, the next-generation sequencing based molecular test detects genomic variations in 213 genes related to familial cardiovascular diseases. Designed to detect the genetic causes of sudden death in young individuals and athletes—such as cardiomyopathies, Long QT, and Marfan syndrome—the panel combines the genetic and clinical information of more than 85,000 individuals from a proprietary database with a comprehensive interpretive report that is reviewed by specialized cardiology geneticists.
“The launch of CardioGxOne allows cardiologists to pinpoint genetic risk of disease for a wide variety of serious cardiac conditions related to sudden cardiac death risk,” says Zeil Rosenberg, MD, vice president for medical affairs at Admera Health. “Launch of the test also marks another milestone in Admera Health’s portfolio expansion to meet the expressed needs of cardiologists and their patients.”
For more information, visit Admera Health.